Weill Cornell Medicine has been awarded a nearly $6.5 million, four-year grant from the Department of Defense as part of a multi-institutional Transformative Breast Cancer Consortium.
A powerful immune-suppressing molecule produced by the body may hold the key to better treatments for autoimmune and inflammatory diseases, as well as for some cancers, according to a study by researchers at Weill Cornell Medicine and the University of Perugia.
